Nov. 12, 2024 — Researchers have identified a potential biomarker of Parkinson's disease progression. According to the new study, patients with a slow progression of ... Oct. 8, 2024 ...

Icalcaprant is under clinical development by Cerevel Therapeutics and currently in Phase I for Bipolar I Disorder.

Joe Parkinson leads The Wall Street Journal's world enterprise team, deploying to the world's biggest breaking stories and piloting deeply reported investigations. His stories often follow ...

Also of note, AbbVie announced strong Phase III results of tavapadon in early Parkinson’s disease. Unfettered access to ...

Earlier this month, the company announced positive results for tavapadon, which met both primary and secondary endpoints in a phase 3 trial for treating early Parkinson's. The company is going to ...

Earlier this month, the company announced positive results for tavapadon, which met both primary and secondary endpoints in a phase 3 trial for treating early Parkinson's. The company is going to ...

Symptoms of Parkinson's disease typically appear gradually and worsen over time. Symptoms and the speed of progression vary from person to person. Early detection of Parkinson's can help people ...

On 9 December 2024, AbbVie announced positive topline results from its pivotal Phase III TEMPO-2 trial, evaluating tavapadon as a flexible-dose (5mg to 15mg, once daily) monotherapy in early Parkinson ...

Bryan Hill has been aware of Parkinson's disease his whole life. His mother was living with early onset Parkinson's when he was born, and through his adolescence, he did what he could to support her.

Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson's disease. The TEMPO-2 trial evaluated the efficacy, safety and tolerability of a ...

One of those people was Tennessee Rep. Antonio Parkinson (D-Memphis). Parkinson said he was devastated when he learned his longtime friend Ellen Granberry was one of two women found shot to ...

Within the Cerevel pipeline, we are very pleased with the positive Phase 3 results and emerging profile of tavapadon in Parkinson’s. And, we remain on track to read out both pivotal studies for ...